Introduction
Biotinidase (BTD) deficiency is an autosomal recessive genetic disorder where the lack of biotinidase results in a biochemical inability to free biotin from its protein bound form and make it available as a cofactor for biotin-dependent carboxylases. These enzymes are responsible for fatty acid synthesis, amino acid catabolism, and gluconeogenesis. Biotinidase enzyme deficiency is caused by a mutation in the BTD gene. More than 80 mutations have been identified in the BTD gene at chromosome locus 3p25 to date. Biotinidase deficiency is not rare with an estimated incidence of almost 1 in 60,000 live births and can present at any time from 1 week to 10 years of age. Carrier frequency is about 1:120 in the general population. Targeted mutation, sequence, deletion/duplication analysis and simple flurometric enzyme assay can help determine the diagnosis. Profound (<10% of mean normal serum enzyme activity) and partial (10-30% of mean normal serum enzyme activity) deficiencies can occur.
Biotinidase deficiency, first distinguished in the early 1980's, has been recognized to cause a wide spectrum of disease. Neurological manifestations include visual impairment (optic atrophy, scotomas), sensorineural hearing loss, seizures (myoclonic, partial seizures, tonic-clonic or infantile spasms), ataxia, neuropathy, and hypotonia. Spinal cord disease is rare but clinical manifestations with progressive spastic paraparesis and ascending weakness have been reported. Biotinidase deficiency can also lead to dermatological disease (seborrheic or atopic dermatitis, alopecia, candidiasis, hair loss, conjunctivitis), immunological deficits, respiratory impairments (tachypnea, hyperventilation, apnea, stridor), feeding and gastrointestinal problems (vomiting, diarrhea), and hepatosplenomegaly. Acute metabolic acidosis may prove to be lethal, if untreated. Screening has been implemented in some areas as the signs and symptoms of the disease are preventable with early treatment. Early initiation of treatment has been shown to prevent further manifestations of the disease and many findings are reversible. The limit of what deficits are irreversible when treatment is delayed is not well defined. Early treatment can prevent hearing loss in children with null mutations in the BTD gene. The pathological correlates for clinical disease and response to treatment are also not frequently correlated in the literature. No other phenotypes are believed to be associated with mutations in the BTD gene.
Clinical report
Our patient was a 22 year old woman who was the only child of two healthy non-consanguinous African American parents. She was born full term after a normal pregnancy with normal development until 7 months when she had multiple episodes of respiratory distress, once requiring intubation for apnea. The patient had visual and auditory decline, developmental regression and hair loss. She also began having seizures characterized by rocking movements, loss of consciousness, head/eye turning, and bilateral extension of upper and lower extremities followed by clonic movements of one or both arms. The diagnosis of biotinidase deficiency was made with genetic testing that revealed carrier status in both parents. The patient was subsequently started on biotin supplementation at age 3 with resolution of alopecia but without improvement of her neurological deficits or seizures.
On examination, she was a thin-built woman who was alert but deaf and blind. She was non-verbal but repeatedly made few grunting sounds. Her self-stimulatory behavior included head banging and hand writhing movements. Truncal tone was decreased. She had increased spasticity in the lower extremities with sustained ankle clonus bilaterally. The patient was wheelchair bound.
Routine and Video EEG monitoring revealed diffuse generalized slowing with extremely frequent multifocal (left more than right) and generalized frontally predominant bursts of spikes and slow spikes and slow waves (see Fig. 1a generalized onset but amplitude asymmetry (left more than right) with amplitude asymmetry (left more than right; see Fig. 1b ). She remained seizure free on a combination of valproic acid and levetiracetam. It is interesting that a recent study in rats has shown that the use of depakote can significantly decrease the levels of serum and liver tissue biotinidase enzyme activity.
1 MRI brain (see Fig. 2a ) showed generalized atrophy, Dandy Walker variant (see Fig. 2b ), cystic encephalomalacia in bifrontal and anterior temporal lobes and periatrial white matter. Cervical spine MRI showed no spinal cord abnormality.
Discussion
Various neuroimaging findings have been reported in patients with biotinidase deficiency such as cerebral atrophy, ventriculomegaly, widened extracerebral spaces, subdural effusions, caudate involvement, basal ganglia calcifications, cortical abnormalities in the parieto-occipital region and restricted diffusion on DWI. 2, 3 Spinal cord findings have included myelopathy. 4 and extensive marked medullary, cervical or thoracic spinal cord demyelination in three Chinese patients. MRI brain findings have included hyperintense T2 signal in periventricular white matter and caudothalamic regions. MRI often demonstrates atrophy with compensatory ventricolomegaly and may also show edema. 6 There have been previous case reports of diffuse periventricular hypodensities particularly in the frontal regions on the CT scan of the brain that resolved completely with treatment. 7, 8 Cystic degeneration has also been reported. 9 Serial CT-scan and MRI studies of the brain have demonstrated a distinct pattern of changes from diffuse low attenuation of the white matter followed by progressive marked cerebral atrophy, which was reversed following biotin treatment. Subcortical spongy lesions have been reported on autopsy and on microscopic examination were characterized by loss of myelination, sponginess, rarefaction and microcysts with an increase in vascularity of the lesions. 10 Necrotizing lesions similar to lesions seen in Leigh's disease or Wernicke's encephalopathy have been reported. However, the most affected areas are the hippocampal and parahippocampal cortex. 11 While some MRI and clinical findings are reversible, some have not been. Cerebral atrophy has been reported to be reversible with early biotin treatment. 8, 12 In our patient destructive lesions were permanent despite treatment since age 3. This demonstrates the irreversibility of brain damage in patients who fail to have biotin supplementation. The lack of normalization of the MRI correlates clinically as the patient failed to improve neurologically. 1 H-MR spectroscopy findings have been reported in a small series of four patients that include high lactate peak, reversal of the choline/creatinine ratio and decreased NAA peaks. 2 Lactate, pyruvate and 3-hydroxyisovaleric are useful biochemical markers that should be measured in blood, CSF and brain tissue. 13 Published data on Long term monitoring EEG studies in patients with biotinidase deficiency could not be found on our literature search. Description of clinical events had raised suspicion of partial extratemporal focus/self-stimulatory behavior and either tonicclonic seizures or partial seizures with secondary generalization. Video EEG supported the diagnosis of symptomatic generalized epilepsy.
